Section Arrow
Quote
FTRE.NASDAQ
- Fortrea Holdings
Quotes are at least 15-min delayed:2025/09/04 11:13 EDT
Regular Hours
Last
 10.495
-0.195 (-1.82%)
Day High 
10.79 
Prev. Close
10.69 
1-M High
11.07 
Volume 
483.46K 
Bid
10.49
Ask
10.5
Day Low
10.35 
Open
10.58 
1-M Low
5.8201 
Market Cap 
970.65M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 9.09 
20-SMA 8.23 
50-SMA 6.57 
52-W High 25.28 
52-W Low 3.97 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-11.35/1.57
Enterprise Value
2.08B
Balance Sheet
Book Value Per Share
6.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.70B
Operating Revenue Per Share
33.93
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADAPAdaptimmune Therapeutics plc0.04875-0.00385-7.32%-- 
PPBTPurple Biotech Ltd0.7859-0.6341-44.65%0PE
ETHZETHZilla Corporation2.28-0.24-9.52%-- 
SGMOSangamo Therapeutics0.531-0.003-0.56%-- 
RXRXRecursion Pharmaceuticals4.4759-0.1541-3.33%-- 
Quotes are at least 15-min delayed：2025/09/04 11:13 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.